Dr. Bar­bara Krebs-Pohl has been pas­sion­ate about sci­ence and medi­cine for as long as she can remem­ber. Over the last 27 years at MorphoSys, both as a sci­ent­ist and as a com­pany exec­ut­ive and leader, she has helped bring innov­at­ive medi­cines to people liv­ing with life-threat­en­ing diseases.

She is MorphoSys’ Chief Busi­ness Officer, respons­ible for driv­ing busi­ness growth and cham­pi­on­ing stra­tegic part­ner­ships. She spear­headed the acquis­i­tion and integ­ra­tion of Con­stel­la­tion Phar­ma­ceut­ic­als into MorphsSys, strength­en­ing the lead­er­ship in onco­logy and expand­ing the pipeline into new areas of unmet med­ical need. Most recently, she was instru­mental in bring­ing about the acquis­i­tion of MorphoSys by Novartis.

Dr. Krebs-Pohl has been lucky enough to travel the world and meet inspir­ing people and ment­ors, who have guided her in her career. As she was sup­por­ted, she strives to encour­age young women to build net­works, find ment­ors and embark on a career in a field where they can pos­it­ively impact the lives of so many people.

Dr. Krebs-Pohl stud­ied chem­istry at Cologne Uni­ver­sity and RWTH Aachen and did her PhD with Prof. Stefan Rose-John at the Uni­ver­sity of Mainz. She worked in the labor­at­ory of Nobel laur­eate Sir Greg Winter at the Uni­ver­sity of Cam­bridge and holds a cer­ti­fic­ate in Busi­ness Admin­is­tra­tion and Man­age­ment from Har­vard Busi­ness School.